Previous 10 | Next 10 |
KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING PR Newswire SYDNEY , Nov. 21, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is please...
2023-11-20 16:43:39 ET More on Kazia Kazia issues update on paxalisib study in CNS lymphoma patients Kazia tumbles on voluntary delisting in Australia For further details see: Kazia Therapeutics gets deficiency notice from Nasdaq
KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING PR Newswire SYDNEY , Nov. 15, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASD...
KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA PR Newswire SYDNEY , Nov. 10, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, ...
2023-11-01 08:53:03 ET Kazia Therapeutics ( NASDAQ: KZIA ) on Wednesday provided a preliminary update from an ongoing study of its paxalisib lead program. Licensed from Genentech in late 2016, paxalisib is an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR...
KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA PR Newswire SYDNEY , Nov. 1, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is ...
KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY PR Newswire SYDNEY , Oct. 23, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, announces that sel...
2023-10-11 08:29:04 ET More on Kazia Seeking Alpha’s Quant Rating on Kazia Historical earnings data for Kazia Financial information for Kazia For further details see: Kazia tumbles on voluntary delisting in Australia
Kazia announces voluntary delisting from ASX PR Newswire SYDNEY , Oct. 11, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (ASX:KZA, NASDAQ:KZIA) ( Kazia or the Company ), an oncology-focused drug development company, announces its intention to de-list fr...
KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS PR Newswire SYDNEY , Oct. 5, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update regardi...
News, Short Squeeze, Breakout and More Instantly...
Kazia Therapeutics Limited Company Name:
KZIA Stock Symbol:
NASDAQ Market:
Kazia Therapeutics Limited Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 0.6% to $128.44 on volume of 203,267,889 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 22.1% to $0.5152 on volume of 200,531,827 shares PROSHARES TRUST (SQQQ) fell 0.7% to $7.46 on volume o...
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...